Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Packaging Should Fit Labeling, FDA's Ganley Says

This article was originally published in The Tan Sheet

Executive Summary

OTC manufacturers should tailor product packaging to fit the labeling required under FDA's final rule rather than "chop away at the labeling rule to make it fit onto the package," Division of OTC Drugs Director Charles Ganley, MD, told industry reps at a working group meeting in Rockville, Md. Nov. 23.

You may also be interested in...



OTC Labeling Trade Dress Issues Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label final rule published in the Jan. 3 Federal Register.

OTC Labeling Trade Dress Issues Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label final rule published in the Jan. 3 Federal Register.

OTC Labeling Trade Dress Issues Resolved In FDA Technical Amendment

Labeling of over-the-counter drug products may include light type on a dark background providing the combination results in a highly readable contrast, FDA asserts in a technical amendment to the OTC label final rule published in the Jan. 3 Federal Register.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel